What question did this study set out to answer?

Characterize recombinant Murine leukemia virus (MLV) protease and compare its biochemical properties, substrate specificity, and inhibitor sensitivity to HIV-1 protease.

April 7, 2006Journal of General Virology

Characterization of the murine leukemia virus protease and its comparison with the human immunodeficiency virus type 1 protease

View Full Paper

Ask AI

Bookmark

Characterize recombinant Murine leukemia virus (MLV) protease and compare its biochemical properties, substrate specificity, and inhibitor sensitivity to HIV-1 protease.
Expressed MLV protease in Escherichia coli, purified the enzyme to homogeneity, and quantified activity using HPLC, photometric, and fluorometric assays.
Evaluated substrate cleavage specificity using oligopeptides modeled after native MLV and HIV-1 cleavage sites and recombinant MLV Gag fragments.
Tested the inhibitory efficacy of established HIV-1 protease inhibitors against purified MLV protease and monitored Gag processing in MLV-infected cell cultures.
Purified recombinant MLV protease demonstrated cleavage specificity identical to virion-extracted enzyme but possessed a higher pH optimum than HIV-1 protease.
HIV-1 protease inhibitors inhibited MLV protease, but all tested compounds demonstrated substantially lower potency against MLV protease than against HIV-1 protease.
Amprenavir exhibited the highest potency among tested inhibitors against MLV protease and effectively suppressed Gag polyprotein processing in MLV-infected cells.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Comparative biochemical analysis reveals distinct enzymatic specificity and lower drug sensitivity in murine leukemia virus protease, suggesting evolutionary divergence from HIV-1 protease.

Cite This Study

Fehér et al. (2006) studied this question.

synapsesocial.com/papers/6a712e2d31a3df82432964bc https://doi.org/10.1099/vir.0.81382-0

View Full Paper

Ask AI

Bookmark

Implication

Comparative biochemical analysis reveals distinct enzymatic specificity and lower drug sensitivity in murine leukemia virus protease, suggesting evolutionary divergence from HIV-1 protease.

Characterization of the murine leukemia virus protease and its comparison with the human immunodeficiency virus type 1 protease

Key Points

Discussion

Implication

Cite This Study

Characterization of the murine leukemia virus protease and its comparison with the human immunodeficiency virus type 1 protease

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider